Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

0
755
Spread the love

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration’s Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and …read more    

Comments are closed.